MIRCETTE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Mircette, and when can generic versions of Mircette launch?
Mircette is a drug marketed by Teva Branded Pharm and is included in one NDA.
The generic ingredient in MIRCETTE is desogestrel; ethinyl estradiol. There are eight drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the desogestrel; ethinyl estradiol profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Mircette
A generic version of MIRCETTE was approved as desogestrel; ethinyl estradiol by DURAMED PHARMS BARR on August 12th, 1999.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for MIRCETTE?
- What are the global sales for MIRCETTE?
- What is Average Wholesale Price for MIRCETTE?
Summary for MIRCETTE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 84 |
Clinical Trials: | 1 |
Patent Applications: | 3,893 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for MIRCETTE |
DailyMed Link: | MIRCETTE at DailyMed |
![MIRCETTE drug patent expirations Drug patent expirations by year for MIRCETTE](/p/graph/s/t/MIRCETTE-patent-expirations.png)
![Drug Prices for MIRCETTE](/p/graph/drug-price/MIRCETTE.png)
![Drug Sales Revenue Trends for MIRCETTE](/p/graph/drug-sales-revenues/MIRCETTE.png)
Recent Clinical Trials for MIRCETTE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Teva Branded Pharmaceutical Products, R&D Inc. | Phase 3 |
Teva Branded Pharmaceutical Products R&D, Inc. | Phase 3 |
US Patents and Regulatory Information for MIRCETTE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Teva Branded Pharm | MIRCETTE | desogestrel; ethinyl estradiol | TABLET;ORAL-28 | 020713-001 | Apr 22, 1998 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MIRCETTE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Teva Branded Pharm | MIRCETTE | desogestrel; ethinyl estradiol | TABLET;ORAL-28 | 020713-001 | Apr 22, 1998 | ⤷ Sign Up | ⤷ Sign Up |
Teva Branded Pharm | MIRCETTE | desogestrel; ethinyl estradiol | TABLET;ORAL-28 | 020713-001 | Apr 22, 1998 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for MIRCETTE
See the table below for patents covering MIRCETTE around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
World Intellectual Property Organization (WIPO) | 9004330 | ⤷ Sign Up | |
Canada | 2001144 | METHODE ET SYSTEME DE CONTRACEPTION (CONTRACEPTION SYSTEM AND METHOD) | ⤷ Sign Up |
New Zealand | 231091 | CONTRACEPTION SYSTEM AND METHOD COMPRISING TIMED ADMINISTRATION OF AN ESTROGEN FOLLOWED BY A PROGESTIN | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |